Halozyme Therapeutics (HALO) Enterprise Value (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Enterprise Value data on file, last reported at -$318.6 million in Q1 2026.

• On a quarterly basis, Enterprise Value rose 57.4% year-over-year to -$318.6 million in Q1 2026; TTM through Mar 2026 was -$318.6 million, a 57.4% increase from a year earlier, with the FY2025 full-year figure at -$142.8 million, up 76.04% from the prior year.
• Enterprise Value for Q1 2026 stood at -$318.6 million, down from -$142.8 million in the prior quarter.
• Over the last five years, Enterprise Value for HALO reached as high as -$142.8 million in Q4 2025 and fell as low as -$786.1 million in Q1 2022.
• Historically, Enterprise Value has averaged -$457.7 million across 5 years, with a median of -$463.5 million in 2024.
• Across the five-year window, Enterprise Value sank 81.97% in 2023 and surged 76.04% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$362.8 million in 2022, then increased by 7.39% to -$336.0 million in 2023, then sank by 77.4% to -$596.1 million in 2024, then jumped by 76.04% to -$142.8 million in 2025, then tumbled by 123.09% to -$318.6 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$318.6 million in Q1 2026, -$142.8 million in Q4 2025, and -$702.0 million in Q3 2025.